CBD Product Safety and Standardization Act of 2023

Bill 118 hr 1628, also known as the CBD Product Safety and Standardization Act of 2023, aims to regulate the production and sale of CBD products in the United States. The bill addresses concerns about the lack of consistency and quality control in the CBD industry, as well as the potential health risks associated with unregulated products.

Under the provisions of the bill, CBD products would be required to meet certain safety and quality standards set by the Food and Drug Administration (FDA). This includes testing for contaminants, accurate labeling of ingredients, and proper dosage information. Manufacturers would also be required to obtain FDA approval before marketing their products.

In addition, the bill establishes a system for tracking and monitoring CBD products from production to sale, in order to ensure compliance with regulations. This would help to prevent the sale of counterfeit or unsafe products on the market. Overall, the CBD Product Safety and Standardization Act of 2023 aims to protect consumers from potential harm and provide them with accurate information about the CBD products they are purchasing. By setting clear standards and regulations for the industry, the bill seeks to promote transparency and accountability among CBD manufacturers and retailers.